Literature DB >> 15609314

Antimicrobial protein hCAP18/LL-37 is highly expressed in breast cancer and is a putative growth factor for epithelial cells.

Johan D Heilborn1, Margareta Frohm Nilsson, Clara I Chamorro Jimenez, Bengt Sandstedt, Niels Borregaard, Emma Tham, Ole E Sørensen, Günther Weber, Mona Ståhle.   

Abstract

Human cathelicidin antimicrobial protein hCAP18/LL-37 is an effector molecule of the nonspecific innate immune system. hCAP18/LL-37 is present in leukocytes and is expressed in skin and other epithelia, where it is upregulated in association with inflammation and injury. In addition, antimicrobial proteins including cathelicidins have been proposed to play a role in the nonspecific defense against tumors. To assess its potential role in tumor host defense, we investigated the expression of hCAP18/LL-37 in a series of breast carcinomas. Unexpectedly, we found that hCAP18/LL-37 was strongly expressed in the tumor cells and not in the adjacent stroma. To test the hypothesis that hCAP18/LL-37 may provide a growth advantage for the tumor cells, we treated human epithelial cell lines with synthetic biologically active LL-37 peptide and found a significant increase in cell proliferation. In addition, transgenic expression of hCAP18 in 2 different human epithelial cell lines resulted in increased proliferation of both cell types. These findings do not support the hypothesis that LL-37 has an antitumor effect, but rather suggest that hCAP18/LL-37 may promote tumor cell growth in breast cancer. 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15609314     DOI: 10.1002/ijc.20795

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  50 in total

1.  Bioengineered human skin: working the bugs out.

Authors:  L Steinstraesser; S Al-Benna; M Kesting; F Jacobsen
Journal:  Mol Ther       Date:  2009-03       Impact factor: 11.454

2.  Understanding tumor-stroma interplays for targeted therapies by armed mesenchymal stromal progenitors: the Mesenkillers.

Authors:  Giulia Grisendi; Rita Bussolari; Elena Veronesi; Serena Piccinno; Jorge S Burns; Giorgio De Santis; Pietro Loschi; Marco Pignatti; Fabrizio Di Benedetto; Roberto Ballarin; Carmela Di Gregorio; Valentina Guarneri; Lino Piccinini; Edwin M Horwitz; Paolo Paolucci; Pierfranco Conte; Massimo Dominici
Journal:  Am J Cancer Res       Date:  2011-05-28       Impact factor: 6.166

Review 3.  Alarmins: awaiting a clinical response.

Authors:  James K Chan; Johannes Roth; Joost J Oppenheim; Kevin J Tracey; Thomas Vogl; Marc Feldmann; Nicole Horwood; Jagdeep Nanchahal
Journal:  J Clin Invest       Date:  2012-08-01       Impact factor: 14.808

Review 4.  Emerging roles of the host defense peptide LL-37 in human cancer and its potential therapeutic applications.

Authors:  William K K Wu; Guangshun Wang; Seth B Coffelt; Aline M Betancourt; Chung W Lee; Daiming Fan; Kaichun Wu; Jun Yu; Joseph J Y Sung; Chi H Cho
Journal:  Int J Cancer       Date:  2010-10-15       Impact factor: 7.396

5.  A deficiency in cathelicidin reduces lung tumor growth in NNK/NTHi-induced A/J mice.

Authors:  Yiwen Yao; Junlu Wu; Hao Zhou; Jenni Firrman; Weidong Xiao; Zujun Sun; Dong Li
Journal:  Am J Cancer Res       Date:  2018-07-01       Impact factor: 6.166

6.  Effects of bacterial infection on airway antimicrobial peptides and proteins in COPD.

Authors:  Ganapathi Iyer Parameswaran; Sanjay Sethi; Timothy F Murphy
Journal:  Chest       Date:  2011-02-24       Impact factor: 9.410

7.  The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells.

Authors:  Seth B Coffelt; Frank C Marini; Keri Watson; Kevin J Zwezdaryk; Jennifer L Dembinski; Heather L LaMarca; Suzanne L Tomchuck; Kerstin Honer zu Bentrup; Elizabeth S Danka; Sarah L Henkle; Aline B Scandurro
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-20       Impact factor: 11.205

8.  DNA from dead cancer cells induces TLR9-mediated invasion and inflammation in living cancer cells.

Authors:  Johanna Tuomela; Jouko Sandholm; Mika Kaakinen; Ankita Patel; Joonas H Kauppila; Joanna Ilvesaro; Dongquan Chen; Kevin W Harris; David Graves; Katri S Selander
Journal:  Breast Cancer Res Treat       Date:  2013-11-10       Impact factor: 4.872

9.  Leucine leucine-37 uses formyl peptide receptor-like 1 to activate signal transduction pathways, stimulate oncogenic gene expression, and enhance the invasiveness of ovarian cancer cells.

Authors:  Seth B Coffelt; Suzanne L Tomchuck; Kevin J Zwezdaryk; Elizabeth S Danka; Aline B Scandurro
Journal:  Mol Cancer Res       Date:  2009-06-02       Impact factor: 5.852

10.  The human cathelicidin LL-37 modulates the activities of the P2X7 receptor in a structure-dependent manner.

Authors:  Linda Tomasinsig; Cinzia Pizzirani; Barbara Skerlavaj; Patrizia Pellegatti; Sara Gulinelli; Alessandro Tossi; Francesco Di Virgilio; Margherita Zanetti
Journal:  J Biol Chem       Date:  2008-09-02       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.